Who Owns Wegovy, and What Does That Mean for UK Patients?

Is Novo Nordisk the same company that makes Ozempic?

Yes. Novo Nordisk makes both Wegovy and Ozempic, and both contain semaglutide. The distinction lies in the licensed indication and the dose. Ozempic (0.5 mg, 1 mg and 2 mg weekly injections) is authorised in the UK for type 2 diabetes, not for weight management. Wegovy (2.4 mg, and now up to 7.2 mg) carries a separate UK marketing authorisation specifically for weight management in adults with obesity or excess weight alongside a weight-related health condition. That difference is not cosmetic — it determines what a prescriber can legally issue the medicine for, what the clinical evidence supports, and how NICE and NHS England have assessed it. The MHRA licenses these as distinct products, and the semaglutide overview on this site explains how the same molecule sits behind several brand names with meaningfully different authorisations. If you are curious about what company owns Wegovy and how that corporate structure works, that page sets out the detail. Novo Nordisk's ownership of both brands means the underlying manufacturing quality and supply chain are consistent, but it also means the company controls pricing and allocation across both products, which has at times affected availability.

Who discovered semaglutide, and how did Wegovy come to exist?

Semaglutide was developed by Novo Nordisk's research teams as a next-generation GLP-1 receptor agonist, building on earlier work with liraglutide (Victoza and Saxenda). Novo Nordisk holds the core patents on the semaglutide molecule. The company ran the global STEP clinical programme, including STEP 1, a 68-week trial that found roughly 15% average weight reduction at the 2.4 mg maintenance dose, published in the New England Journal of Medicine. That evidence base underpinned both the US FDA approval and the UK MHRA authorisation. More recently, Novo Nordisk extended the Wegovy dose range: the MHRA approved a 7.2 mg maintenance option, with a dedicated single-dose pen confirmed in April 2026. If you want the detail on how Wegovy is manufactured and what the supply chain looks like, that covers the production side specifically. For a focused explanation of who owns the Wegovy drug and what that means for patients, that page covers the ownership question in full. Novo Nordisk's involvement does not end at discovery, the company is responsible for pharmacovigilance, post-market safety monitoring, and supplying updated safety information to the MHRA throughout the product's licensed life.

Does Novo Nordisk's ownership affect how Wegovy is prescribed or accessed in the UK?

Ownership shapes access in a few practical ways. First, Novo Nordisk sets the list price for Wegovy in the UK, which influences what private clinics and pharmacies pay to stock it. NICE appraised Wegovy for NHS use in technology appraisal TA875, recommending it for up to two years within specialist weight management services, the NHS negotiates its own supply terms with Novo Nordisk separately from the private market. Second, because Novo Nordisk is the sole manufacturer, any production constraint or allocation decision at company level ripples through to availability everywhere. That is part of why the cost of Wegovy in the UK has shifted at various points and why supply has sometimes been limited. Third, the Black Triangle (▼) status means Novo Nordisk is required to submit additional safety data to the MHRA on an ongoing basis; patients and prescribers can report suspected side effects via the MHRA Yellow Card scheme. None of this changes the fundamentals for someone considering treatment: Wegovy remains a prescription-only medicine that requires a clinical assessment, regardless of which pharmacy supplies it or how Novo Nordisk structures its pricing. The full Wegovy treatment guide covers eligibility, how the weekly injection works in practice, and what ongoing clinical support should look like.

Is Wegovy available through a regulated UK pharmacy?

Wegovy is legally available in the UK only on a private or NHS prescription issued by a qualified prescriber after a proper clinical assessment. At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber, not software. Medicines are sourced through the licensed UK supply chain, which means the Wegovy a patient receives comes from Novo Nordisk's authorised distribution network, the same origin as any hospital or GP surgery supply. The who we are page sets out our GPhC registration and how to verify us on the pharmacy register. If you have further questions about the process, the FAQs page covers the most common ones. For anyone ready to explore whether Wegovy or another licensed treatment is clinically appropriate for them, speaking to our prescribers is the right starting point.